IMPL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 gruod. 2023 @ 22:58):

Stats
Šios dienos apimtis	720 030
Vidutinė apimtis	1.02M
Rinkos kapitalizacija	956 000
EPS	$0 ( 2024-03-22 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0128
ATR14	$0.116 (114.74%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Smith Brandon D	Buy	0
2023-12-15	Vivo Capital Viii, Llc	Sell	87 934	Common Stock
2023-12-18	Vivo Capital Viii, Llc	Sell	209 029	Common Stock
2023-12-19	Vivo Capital Viii, Llc	Sell	208 657	Common Stock
2023-12-15	Vivo Capital Viii, Llc	Sell	12 066	Common Stock

INSIDER POWER
47.39
Last 95 transactions
Buy: 8 739 782 \| Sell: 5 181 184

Tūris Koreliacija

Ilgas: 0.42 (neutral)

Trumpas: -0.39 (neutral)

Signal:(41.758) Neutral

Impel Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
FNWB	0.921
EGBN	0.909
CNSL	0.904
DIBS	0.901
ALTO	0.896
FTXO	0.892
FFIC	0.885
FRST	0.883
CSTE	0.881
CCSI	0.88

10 Labiausiai neigiamai susiję koreliacijos
LMNR	-0.937
WIRE	-0.927
NRDS	-0.918
MHUA	-0.893
PEGA	-0.892
SKYT	-0.889
OBT	-0.889
MORF	-0.886
HTBI	-0.884
HUGE	-0.882

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Impel Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.45
( neutral )

0.62
( weak )

0.00
( neutral )

0.64
( weak )

0.21
( neutral )

-0.57
( weak negative )

Impel Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	$12.65M
Bruto pelnas:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2022
Pajamos:	$12.65M
Bruto pelnas:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2021
Pajamos:	$668 000
Bruto pelnas:	$-23 000.00 (-3.44 %)
EPS:	$-5.25

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.47

Financial Reports:

No articles found.

Impel Pharmaceuticals

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.